ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
FDA rejects Insys’ opioid spray Buvaya
pharmaceutical-technology
August 01, 2018The US Food and Drug Administration (FDA) has sent a complete response letter to Insys Therapeutics rejecting its new drug application for Buvaya, a sublingual spray form of buprenorphine, an opioid analgesic.
Pharma Sources Insight January 2025
